Herceptin May Be of Little Use in Immune Cell-Heavy Breast Ca

December 11, 2014 6:00 PM

2 0

SAN ANTONIO -- HER2-positive breast cancers with a high level of immune cell infiltration might not benefit from the addition of trastuzumab (Herceptin) to chemotherapy, a trial analysis suggested.

The 10% of patients with stromal tumor-infiltrating lymphocyte-predominant breast cancer in the Alliance N9831 trial showed similar recurrence-free survival (RFS) whether they received chemotherapy alone or with trastuzumab (10-year rate 90.9% versus 80.0%, P=0.21), Edith A. Perez, MD, of the Mayo C...

Read more

To category page